Key Points
- Insider sale: David Moatazedi sold 10,539 shares of Evolus on December 22 at an average price of $7.15, totaling $75,353.85, in a transaction disclosed to the SEC.
- After the sale Moatazedi still directly owns 354,388 shares (a 2.89% reduction), valued at about $2.53 million based on the sale price.
- Evolus trades near $6.66 with a market cap of $431.7 million, is 90.69% institutionally owned, and carries a consensus analyst rating of “Moderate Buy” with an average price target of $20.80.
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 2,261 shares of Evolus stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $16,166.15. Following the sale, the insider directly owned 356,821 shares of the company's stock, valued at $2,551,270.15. This represents a 0.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Evolus Price Performance
Shares of Evolus stock opened at $6.66 on Tuesday. The stock has a market cap of $431.70 million, a price-to-earnings ratio of -7.24 and a beta of 0.87. The firm's 50-day moving average is $6.91 and its two-hundred day moving average is $7.49. Evolus, Inc. has a 1 year low of $5.71 and a 1 year high of $17.12.
Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%.The business had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. On average, equities analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current year.
Institutional Trading of Evolus
Several institutional investors have recently bought and sold shares of EOLS. Rice Hall James & Associates LLC boosted its stake in Evolus by 17.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company's stock worth $7,177,000 after purchasing an additional 172,846 shares during the period. Pinnacle Associates Ltd. acquired a new position in Evolus during the 2nd quarter worth approximately $6,318,000. PDT Partners LLC purchased a new stake in shares of Evolus during the 1st quarter worth $730,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Evolus in the 2nd quarter worth approximately $22,431,000. Finally, Frontier Capital Management Co. LLC grew its holdings in Evolus by 37.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company's stock valued at $15,333,000 after purchasing an additional 457,533 shares during the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have recently commented on EOLS. Needham & Company LLC reiterated a "hold" rating on shares of Evolus in a research note on Wednesday, December 24th. Wall Street Zen raised Evolus from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th. BTIG Research reiterated a "buy" rating and set a $18.00 price target on shares of Evolus in a research note on Monday, September 8th. Mizuho reduced their price objective on Evolus from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Monday, December 1st. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Evolus in a report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $20.80.
Check Out Our Latest Stock Analysis on Evolus
About Evolus
(
Get Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
